擅長： 肺癌、胸膜間皮瘤等胸部腫瘤、乳腺癌、肉瘤；肺癌規(guī)范化、個(gè)體化多學(xué)科綜合治療以及實(shí)體瘤多藥耐藥及逆轉(zhuǎn)

簡介： 內(nèi)科學(xué)博士、腫瘤學(xué)博士后。北京大學(xué)腫瘤醫(yī)院胸部腫瘤內(nèi)一科(原胸部腫瘤內(nèi)科)主任醫(yī)師、 教授、 博士生導(dǎo)師，科主任。中國抗癌協(xié)會(huì)肺癌專業(yè)委員會(huì)常委，CSCO執(zhí)行委員，北京市醫(yī)學(xué)會(huì)腫瘤專業(yè)委員會(huì)副主任委員，中國臨床腫瘤學(xué)會(huì)小細(xì)胞肺癌專家委員會(huì)副主任委員，中國臨床腫瘤學(xué)會(huì)肉瘤專家委員會(huì)副主任委員。Clin.Lung Cancer, 中華結(jié)核與呼吸雜志及中國肺癌雜志、Thoracic Cancer編委，中國胸部腫瘤協(xié)作組(Chinese Thoracic Oncology Group, CTONG)委員。迄今培養(yǎng)博士研究生5名，碩士研究生20余名。 多年來一直致力于肺癌規(guī)范化、個(gè)體化、多學(xué)科綜合治療及相關(guān)研究。2002年12月至2004年12月接受美國NCI“Oncology Research Faculty Development Program”資助，在M.D.Anderson Cancer Center胸部腫瘤內(nèi)科學(xué)習(xí)肺癌為主實(shí)體瘤臨床治療及相關(guān)應(yīng)用基礎(chǔ)研究，豐富了肺癌個(gè)體化多學(xué)科綜合治療臨床經(jīng)驗(yàn)，對肺癌發(fā)生發(fā)展過程中分子機(jī)制及其相關(guān)研究有深入了解與認(rèn)識(shí)。積極探尋肺癌預(yù)測分子靶向和化療治療療效、預(yù)后的分子預(yù)測標(biāo)志，部分研究成果已應(yīng)用于臨床實(shí)踐。 專業(yè)特長 從事腫瘤臨床工作多年，對胸部腫瘤尤其是肺癌、胸膜間皮瘤、胸腺腫瘤的規(guī)范化、個(gè)體化、多學(xué)科綜合治療具有豐富經(jīng)驗(yàn)及深厚的學(xué)術(shù)造詣，尤其在肺癌基因分型個(gè)體化診治方面引領(lǐng)國內(nèi)走向，擅長將臨床實(shí)踐與轉(zhuǎn)化研究成果有機(jī)結(jié)合，指導(dǎo)臨床。 研究成果 作為課題負(fù)責(zé)人多次承擔(dān)國家自然科學(xué)基金、國家863科技支撐項(xiàng)目、北京市首發(fā)基金等研究。國內(nèi)外腫瘤核心期刊J Clin. Oncol, Cancer Research, Clin Cancer research等雜志發(fā)表論文100余篇。2008年入選國家“十、百、千”人才計(jì)劃。2010年獲得國家自然科學(xué)基金“杰出青年基金”資助。獲2011年中國青年女科學(xué)家獎(jiǎng)及北京市學(xué)科帶頭人基金。先后獲得中國抗癌協(xié)會(huì)科技進(jìn)步一等獎(jiǎng)、北京市科技進(jìn)步三等獎(jiǎng)、中華醫(yī)學(xué)會(huì)醫(yī)學(xué)獎(jiǎng)三等獎(jiǎng)、教育部科技成果二等獎(jiǎng)、華夏科技成果二等獎(jiǎng)等。 社會(huì)任職 兼任中國抗癌協(xié)會(huì)肺癌專業(yè)委員會(huì)常務(wù)委員，北京醫(yī)學(xué)會(huì)腫瘤專業(yè)委員會(huì)副主任委員，中國臨床腫瘤協(xié)會(huì)(CSCO)執(zhí)行委員，中國抗癌協(xié)會(huì)小細(xì)胞肺癌專家委員會(huì)副主任委員，中國抗癌協(xié)會(huì)肉瘤專家委員會(huì)副主任委員;《中華結(jié)核與呼吸雜志》編委、《中國肺癌雜志》編委、《Clinical Lung cancer》、《Thoracic Oncology》編委。 主要論著 近期代表性論著(PI或第一作者) 1.Hua Bai, Zhijie Wang, Keneng Chen, Jun Zhao, Shuhang Wang, Qinghua Zhou, Minglei Zhuo, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Zhen Liang, Yuyan Wang1, Xiaozheng Kang, Jie Wang. Influence of Chemotherapy on EGFR Mutation Status for Patients with Non-small Cell Lung Cancer. J Clin Oncol，2012, 30:3077-83. (PI) 2.Zhijie Wang, Tongtong An, Tony Mok, Jie Wang et al. A retrospective analysis of maintenance versus delayed EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chinese Journal of Cancer Research.2012,24(1):1-12. (PI) 3.Zhijie Wang, Xuchao Zhang, Hua Bai, Jun Zhao, Minglei Zhuo, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Shuhang Wang, Yuyan Wang, Yilong Wu and Jie Wang. NSCLC patients with EML4-ALK rearrangement cannot benefit from EGFR-TKI. Oncology, 2012. (PI) 4.Mei na Wu, Jun Zhao, Sonya Wei Song，Hua Bai，Minglei Zhuo ,Shuhang Wang, Lu Yang, Tongtong An, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Jie Wang. Plasma EGFR mutations are not associated with response to first-line chemotherapy but with prognosis in the Chinese patients with advanced non-small cell lung cancer. lung cancer 2010, 67(3):343-347 (PI) 5.Shuhang wang , Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Meina Wu. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced NSCLC. Clin Cancer Res 2010, 15,16(4):1324-1330 (PI) 6.Hua Bai, Li Mao, Shuhang Wang, Jun Zhao, Lu Yang, Tongtong An, Xin Wang, Jianchun Duan Meina Wu, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Yuye Wang, Jie Wang. EGFR Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. J Clin Oncol , 2009,( 27)：2663-2669 (PI) 7.Xin Wang , Jun Zhao , Lu Yang, Li Mao，Jie Wang.et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol (2010) 27:484–490 (PI) WANG J. Manisha Bhutani1, Ashutosh K. DNMT3B Variants Regulate DNA Methylation in a Promoter-Specific Manner. Cancer Res 2007,67: 10647-10652 8.Jun Zhao, Zhi-jie Wang, Jian-chun Duan. Jie Wang .et al. A phase II Clinical Trial of Celecoxib Combined with Platinum-based Regimen as First-line Chemotherapy for Advanced Non-small Cell Lung Cancer Patients with Cyclooxygenase-2 Positive Expression. Chin J Cancer Res 2009 21(1):1-12 (PI) 9.Ning-hong Liu, Hua Bai，Lu Yang, ming-lei Zhuo, Shu-hang Wang,Jun Zhao,Jie Wang. Expression of DDNMT3B Variants and its association with estrogen/progestogen receptor status in breast cancer. Chin J Cancer Res 2009, 21(3):229-234 (PI) 10.Jianchun Duan, Lu Yang, Jie Wang, Meina Wu, Tongtong An, Jun Zhao. Retrospective analysis of cetuximab combination with chemotherapy in advanced non-small-cell lung cancer. Chin J Cancer Res 2009,21(3): 229-234 (PI) Wang shuhang, liu ninhong, wang jie,baihua and mao li ,et al. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter specific DNA methylation in non-small cell lung cancer. Chinese Med J 2008;121(17):1712-1721 (PI)